Freeport-McMoRan Inc. (FCX) Stock Forecast
Data as of Aug 1, 2026Basic Materials · Current price $62.84 (-0.93%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 23, 2026 | Daniel Major | UBS | $70.00 | +11.4% |
| Jan 5, 2026 | Christopher LaFemina | Jefferies | $68.00 | +8.2% |
| Dec 15, 2025 | Carlos De Alba | Morgan Stanley | $53.00 | -15.7% |
| Nov 19, 2025 | Katja Jancic | BMO Capital | $47.00 | -25.2% |
| Nov 19, 2025 | Orest Wowkodaw | Scotiabank | $47.00 | -25.2% |
| Oct 28, 2025 | Orest Wowkodaw | Scotiabank | $51.00 | -18.8% |
| Sep 25, 2025 | Brian MacArthur | Raymond James | $46.00 | -26.8% |
| Sep 24, 2025 | Orest Wowkodaw | Scotiabank | $45.00 | -28.4% |
| Sep 24, 2025 | Christopher LaFemina | Jefferies | $46.00 | -26.8% |
| Sep 24, 2025 | Katja Jancic | BMO Capital | $48.00 | -23.6% |
| Jul 11, 2025 | Daniel Major | UBS | $50.00 | -20.4% |
| Jul 8, 2025 | Ralph Profiti | Stifel Nicolaus | $56.00 | -10.9% |
| Apr 16, 2025 | Timna Tanners | Wolfe Research | $39.00 | -37.9% |
| Oct 8, 2024 | Orest Wowkodaw | Scotiabank | $53.00 | -15.7% |
| Sep 30, 2024 | Orest Wowkodaw | Scotiabank | $52.00 | -17.2% |
| Sep 19, 2024 | Carlos De Alba | Morgan Stanley | $58.00 | -7.7% |
| Sep 4, 2024 | Curt Woodworth | UBS | $55.00 | -12.5% |
| Jul 24, 2024 | Brian MacArthur | Raymond James | $53.00 | -15.7% |
| Jun 21, 2024 | Carlos De Alba | Morgan Stanley | $62.00 | -1.3% |
| May 14, 2024 | Curt Woodworth | UBS | $54.00 | -14.1% |
Top Analysts Covering FCX
FCX vs Sector & Market
| Metric | FCX | Basic Materials Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.18 | 2.36 | 2.42 |
| Analyst Count | 22 | 7 | 19 |
| Target Upside | +15.2% | +120.2% | +17.1% |
| P/E Ratio | 33.25 | -10.77 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $25.69B | $28.91B | $31.26B | 5 |
| 2027-03-31 | $7.15B | $8.00B | $9.07B | 4 |
| 2027-06-30 | $7.56B | $8.46B | $9.59B | 3 |
| 2027-09-30 | $8.09B | $9.05B | $10.26B | 3 |
| 2027-12-31 | $8.20B | $9.18B | $10.40B | 3 |
| 2028-03-31 | $7.89B | $8.83B | $10.01B | 2 |
| 2028-06-30 | $7.80B | $8.73B | $9.89B | 5 |
| 2028-09-30 | $7.77B | $8.69B | $9.85B | 4 |
| 2028-12-31 | $7.77B | $8.69B | $9.85B | 4 |
| 2029-12-31 | $33.61B | $37.78B | $42.29B | 12 |
| 2030-12-31 | $30.99B | $34.84B | $39.00B | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $2.21 | $2.90 | $3.43 | 11 |
| 2027-03-31 | $0.76 | $0.89 | $1.04 | 3 |
| 2027-06-30 | $0.82 | $0.95 | $1.11 | 3 |
| 2027-09-30 | $0.85 | $0.99 | $1.16 | 4 |
| 2027-12-31 | $0.87 | $1.00 | $1.18 | 3 |
| 2028-03-31 | $0.95 | $1.10 | $1.29 | 4 |
| 2028-06-30 | $0.90 | $1.04 | $1.22 | 4 |
| 2028-09-30 | $0.89 | $1.03 | $1.21 | 6 |
| 2028-12-31 | $0.88 | $1.02 | $1.20 | 4 |
| 2029-12-31 | $3.54 | $4.14 | $4.78 | 3 |
| 2030-12-31 | $2.70 | $3.15 | $3.64 | 3 |
Frequently Asked Questions
What is the analyst consensus for FCX?
The consensus among 22 analysts covering Freeport-McMoRan Inc. (FCX) is Buy with an average price target of $71.44.
What is the highest price target for FCX?
The highest price target for FCX is $70.00, set by Daniel Major at UBS on 2026-01-23.
What is the lowest price target for FCX?
The lowest price target for FCX is $28.00, set by Matt Murphy at Barclays on 2021-10-22.
How many analysts cover FCX?
22 analysts have issued ratings for Freeport-McMoRan Inc. in the past 12 months.
Is FCX a buy or sell right now?
Based on 22 analyst ratings, FCX has a consensus rating of Buy (2.18/5) with a +15.2% upside to the consensus target of $71.44.
What are the earnings estimates for FCX?
Analysts estimate FCX will report EPS of $2.90 for the period ending 2026-12-31, with revenue estimated at $28.91B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.